Pharmacy

Share to Twitter Share to Linkedin The Swiss government has approved Zurich's plan to launch a trial program for the consumption and sale of cannabis, expected to start this summer. Switzerland is expanding its pilot scheme on cannabis legalization to study the effects of legalization on the population. The pilot program aims to provide a clearer picture of the impact of cannabis legalization in the country. The Federal Office of Public Health (FOPH), Switzerland's federal government's center for public health, approved on Tuesday, March 21, the Züri Can - Cannabis with Responsibility , a project designed by the collaboration between the Zurich city council and the Zurich University Hospital, which aims to study the impact of regulated cannabis supply on the consumption and health of consumers. The study investigates how the consumption and health of participants are affected by purchasing selected cannabis products from controlled cultivation … [Read more...] about Zurich Set To Legalize Cannabis In Swiss Trial Program

Share to Twitter Share to Linkedin Walgreens Boots Alliance (NASDAQ: WBA) is scheduled to report its fiscal Q2 2023 results on Tuesday, March 28. We expect the company to post revenue and earnings slightly below the street expectations, partly due to fewer Covid-19 vaccine administrations vs. the prior year quarter. That said, the company expects strong growth for its international business in Q2. Although we expect the company to post a downbeat Q2, we believe its stock has more room for growth, as discussed below. Our interactive dashboard analysis on Walgreens Earnings Preview has additional details (1) Revenues expected to be below the consensus estimates Trefis estimates Walgreens’ Q2 2023 revenues to be around $33.2 billion, slightly below the $33.4 billion consensus estimate. This compares with the $33.8 billion revenue the company garnered in the prior-year quarter. The company should benefit from growth in the international … [Read more...] about What To Expect From Walgreens’ Q2?

Share to Twitter Share to Linkedin Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list price, but sometimes even larger. These discounts are supposed to improve the capacity of the clinics and hospitals serving a disproportionate share of low-income and uninsured patients. More and more, this is not how the program is working. Instead of subsidizing a small number of clinics and hospitals, 340B has become the second largest drug discount program in the country. Over the most recent 5 years, the value of 340B drug purchases have grown over 22% annually. A large contributor to this expansion is the Affordable Care Act (ACA) that increased the size of the … [Read more...] about A Bipartisan Regulatory Reform Opportunity: 340B